These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 26359571)
1. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Lee SM; Bae SK; Jung SJ; Kim CK Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571 [TBL] [Abstract][Full Text] [Related]
2. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403 [TBL] [Abstract][Full Text] [Related]
3. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979 [TBL] [Abstract][Full Text] [Related]
4. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Na II; Byun BH; Kim KM; Cheon GJ; Choe du H; Koh JS; Lee DY; Ryoo BY; Baek H; Lim SM; Yang SH; Kim CH; Lee JC Lung Cancer; 2010 Jan; 67(1):76-80. PubMed ID: 19371962 [TBL] [Abstract][Full Text] [Related]
5. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275 [TBL] [Abstract][Full Text] [Related]
6. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710 [TBL] [Abstract][Full Text] [Related]
7. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms. Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618 [TBL] [Abstract][Full Text] [Related]
9. Value of Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298 [TBL] [Abstract][Full Text] [Related]
11. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754 [TBL] [Abstract][Full Text] [Related]
12. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
13. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma. Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729 [TBL] [Abstract][Full Text] [Related]
14. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. Han JY; Choi JJ; Kim JY; Han YL; Lee GK BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791 [TBL] [Abstract][Full Text] [Related]
15. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
16. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. Cho A; Hur J; Moon YW; Hong SR; Suh YJ; Kim YJ; Im DJ; Hong YJ; Lee HJ; Kim YJ; Shim HS; Lee JS; Kim JH; Choi BW BMC Cancer; 2016 Mar; 16():224. PubMed ID: 26979333 [TBL] [Abstract][Full Text] [Related]
17. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis. Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083 [TBL] [Abstract][Full Text] [Related]
18. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Satoh Y; Onishi H; Nambu A; Araki T Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640 [TBL] [Abstract][Full Text] [Related]
19. Correlation between EGFR mutation status and F Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196 [TBL] [Abstract][Full Text] [Related]
20. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer. Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]